University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
David Y. Oh, MD, PhD

David Y. Oh, MD, PhD

Assistant Adjunct Professor, Division of Hematology/Oncology; Medical Oncologist, Cancer Immunotherapy Program, UCSF

Cancer Center Program Memberships

Cancer Immunology

Research Summary

I am a physician-scientist experienced in clinical and translational laboratory efforts to understand and improve upon cancer immunotherapies.

Clinically, I see patients in the Cancer Immunotherapy Program where I am an attending physician, principal investigator, and co-investigator on early-phase/first-in-human trials testing novel immunotherapies in advanced solid tumors, with a particular focus on genitourinary malignancies. This includes high-risk modalities such as bispecific T cell engaging therapies, immune agonist antibodies, intratumoral immunotherapy, and adoptive cell therapies.

In the laboratory, I study samples from prostate and bladder cancer patients treated with immunotherapy using unbiased platforms such as single-cell RNA sequencing and T cell receptor sequencing. The goal of this work is to discover and validate novel T cell populations and antigenic specificities that are responsible for anti-tumor efficacy as well as immune-related adverse events (IRAEs) resulting from treatment.


  • Harvard College, Cambridge, MA, AB, 06/2000, Biochemical Sciences
  • Stanford University School of Medicine, Stanford, CA, MD, 06/2011, Medicine
  • Stanford University School of Medicine, Stanford, CA, PhD, 06/2011, Molecular and Cellular Physiology
  • University of California, San Francisco, CA, Residency, 06/2014, Internal Medicine
  • University of California, San Francisco, CA, Fellowship, 06/2017, Hematology/Oncology

Professional Experience

  • 1997-2000
    Undergraduate honors thesis researcher with Dr. Michael Carroll, Center for Blood Research, Harvard Medical School
  • 2000-2001
    Research Technician with Dr. Judy Lieberman, Center for Blood Research, Harvard Medical School
  • 2011-2014
    Internship and Residency, Department of Medicine, Categorical Track, UCSF
  • 2014-2017
    Clinical Fellowship, Hematology/Oncology, Genitourinary Medical Oncology and Cancer Immunotherapy Programs, Department of Medicine, UCSF
  • 2017-2018
    Clinical Instructor, Non-ACGME Fellow, Hematology/Oncology, Genitourinary Medical Oncology and Cancer Immunotherapy Programs, Department of Medicine, UCSF
  • 2015-2018
    Postdoctoral Fellowship with Dr. Lawrence Fong, UCSF
  • 2018-present
    Assistant Adjunct Professor, Hematology/Oncology, Genitourinary Medical Oncology and Cancer Immunotherapy Programs, Department of Medicine, UCSF

Honors & Awards

  • 9/2001-6/2011
    Medical Scientist Training Program awardee
  • 3/2010
    Keystone Symposia Travel Scholarship
  • 6/2015
    UCSF Hematology/Oncology Clinical Fellow Award (selected by Medicine housestaff for patient care, teaching, professionalism)
  • 1/2016
    UCSF Hematology/Oncology 2016 Award for Excellence in Fellowship Research
  • 4/2016
    Merit Award, Conquer Cancer Foundation of American Society of Clinical Oncology
  • 6/2017
    Young Investigator Award, Conquer Cancer Foundation of American Society of Clinical Oncology
  • 5/2018
    Young Investigator Award, Bladder Cancer Advocacy Network
  • 7/2018
    Young Investigator Award, Prostate Cancer Foundation

Selected Publications

  1. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 Jun 03.
    View on PubMed
  2. Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. J Immunother Cancer. 2020 May; 8(1).
    View on PubMed
  3. Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L. TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer. Front Immunol. 2019; 10:2985.
    View on PubMed
  4. Hammami MB, Gill R, Thiruvengadam N, Oh DY, Beck K, Mahadevan U, Kattah MG. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. Dig Dis Sci. 2019 03; 64(3):685-688.
    View on PubMed
  5. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019 02 19; 50(2):477-492.e8.
    View on PubMed
  6. Oh DY, Fong L. Immunity in the Time of Metastases. Immunity. 2018 12 18; 49(6):1002-1003.
    View on PubMed
  7. Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. Oncoimmunology. 2019; 8(1):e1486953.
    View on PubMed
  8. Oh DY,* Cham J,* Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. *co-first author.. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. Cancer Res. 2017; 77(6):1322-1330.
    View on PubMed
  9. David Yoonsuk Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong. Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients. Journal of Clinical Oncology. 2016 May 20; 34(15_suppl):3029-3029.
    View on PubMed
  10. Oh DY, Venook AP, Fong L. On the Verge: Immunotherapy for Colorectal Carcinoma. J Natl Compr Canc Netw. 2015 Aug; 13(8):970-8.
    View on PubMed
  11. Ehrlich LI,* Oh DY,* Weissman IL, Lewis RS. *co-first author.. Differential contribution of chemotaxis and substrate restriction to segregation of immature and mature thymocytes. Immunity. 2009; 31(6):986-98.
    View on PubMed
  12. Bhakta NR, Oh DY, Lewis RS. Calcium oscillations regulate thymocyte motility during positive selection in the three-dimensional thymic environment. Nat Immunol. 2005 Feb; 6(2):143-51.
    View on PubMed
  13. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003 Mar 07; 112(5):659-72.
    View on PubMed
  14. Beresford PJ, Zhang D, Oh DY, Fan Z, Greer EL, Russo ML, Jaju M, Lieberman J. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem. 2001 Nov 16; 276(46):43285-93.
    View on PubMed
  15. Gommerman JL,* Oh DY,* Zhou X, Tedder TF, Maurer M, Galli SJ, Carroll MC. *co-first author.. A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J Immunol. 2000; 165(12):6915-21.
    View on PubMed

Go to UCSF Profiles, powered by CTSI